Vitamin D supplementation has been proposed as a treatment for Coronavirus Disease COVID based on experimental data and data from small and uncontrolled observational studies. This multicenter, randomized, controlled, open-label, superiority trial involved collaboration of 9 medical centers in France.
Eligible and consenting patients were randomly allocated to either a single oral high-dose , IU or standard-dose 50, IU cholecalciferol administered under medical supervision within 72 hours after the diagnosis of COVID Participants and local study staff were not masked to the allocated treatment, but the Steering Committee and the Data and Safety Monitoring Board were masked to the randomization group and outcome data during the trial.
The primary outcome was day overall mortality. High-dose cholecalciferol did not result in more frequent adverse effects compared to the standard dose. The open-label design and limited study power are the main limitations of the study. In this randomized controlled trial RCT , we observed that the early administration of high-dose versus standard-dose vitamin D3 to at-risk older patients with COVID improved overall mortality at day The effect was no longer observed after 28 days.
Lire la suite sur le site de Plos Medicine. Allez plus loin : - Lire Β« Covid Methods and findings This multicenter, randomized, controlled, open-label, superiority trial involved collaboration of 9 medical centers in France. Conclusions In this randomized controlled trial RCT , we observed that the early administration of high-dose versus standard-dose vitamin D3 to at-risk older patients with COVID improved overall mortality at day Jeu Mer Ven Lun Grippe et covid19 : vaccinez-vous!
C'est gratuit. Plus que 11 jours pour candidater au 4e Prix Berna. Charger plus Suivre sur Instagram.
